There were no significant differences in terms of overall response rates, overall survival and time to progression between CEOP and CNOP in the treatment of intermediate- and high-grade NHL. Patients with low or low intermediate IPI risk treated with either CEOP or CNOP showed significantly better survival, response rates and time to progression than those with high intermediate or high IPI risk. Therefore, new improved therapeutic approaches should be developed for the treatment of high IPI risk patients.
Andreas H. Sarris, Vali Papadimitrakopoulou, Meletios A Dimopoulos, Terry Smith, William Pugh, Chul S. Ha, Peter McLaughlin, David L. Callender, James D. Cox, Fernando Cabanillas
George Papaxoinis, Sotirios G. Papageorgiou, Dimitra Rontogianni, V. Kaloutsi, George Fountzilas, Nikolaos Pavlidis, Meletios A Dimopoulos, Constantinos Tsatalas, Nikolaos I. Xiros, Theofanis Economopoulos
Theofanis Economopoulos, Sotirios G. Papageorgiou, Dimitra Rontogianni, V. Kaloutsi, George Fountzilas, Constantinos Tsatalas, Nikolaos Pavlidis, Dimitrios Pectasides, E. Papageorgiou, Meletios A Dimopoulos
Meletios A Dimopoulos, George Fountzilas, E. Papageorgiou, Christos Kiamouris, George Mantzios, Athanassios Anagnostopoulos, C. Nicolaides, Theofanis Economopoulos
Discussion(0)
No comments yet. Be the first to comment.